Matthew Pauls

This profile gathers the share dealings of Matthew Pauls across 3 companies, led by Savara Inc, Pelthos Therapeutics Inc. and Soleno Therapeutics Inc. We count 23 filings; the first trade dates from 21 May 2021 and the latest from 2 October 2026.

On the open market, the record shows 5 purchases worth €54k and 6 sales worth €403k. Netting one side against the other leaves €349k of net selling. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 9 share grants and 2 option exercises. So far in 2026, the count stands at no purchases and 5 sales.

In size, the median ticket on the buying side is €9,716. 4 out of 5 purchases came within 30 days of a purchase by at least one other insider of the same company. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. Ninety days after publication, 5 purchases show a median change of -6.0%, with the price up in 40% of them. Past outcomes like these are no guarantee of what comes next.

Most recently, on 6 October 2026, the filings show an open-market sale worth €15k in Pelthos Therapeutics Inc. The clock since the last published purchase (8 December 2021) now reads 1,775 days. Typically, a trade is published a median of 4 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.